CD20 Monoclonal Antibody (AISB12), eBioscience™, Invitrogen™

Description

• Description: The AISB12 monoclonal antibody reacts with mouse CD20
• CD20 is a B cell-specific 32kDa membrane protein involved in intracellular calcium regulation
• CD20 expression begins after the induction of CD19 during development, and is coexpressed with IgM during the pre-B to immature B cell transition in bone marrow
• Expression then increases during maturation with almost all mature cells expressing some level of CD20
• The human CD20 antigen has proven to be an effective immunotherapeutic target in B cell lymphoma and several autoimmune diseases including rheumatoid arthritis and type I diabetes
• CD20 consists of 4 transmembrane domains and a 44 amino acid extracellular loop domain where AISB12 binds
• Applications Reported: This AISB12 antibody has been reported for use in flow cytometric analysis and western blotting
• Applications Tested: This AISB12 antibody has been tested by immunoblot on A20 cell lysates and flow cytometry on mouse splenocytes
• Purity: Greater than 90%, as determined by SDS-PAGE
• Aggregation: Less than 10%, as determined by HPLC
• Filtration: 0.2 μm post-manufacturing filtered
• CD20 is a non-glycosylated surface phosphoprotein that has a molecular weight range of 33-37 kDa depending on the degree of phosphorylation
• CD20 is expressed on mature and most malignant B cells, in a subpopulation of T lymphocytes and follicular dendritic cells
• CD20 expression on B cells is synchronous with the expression of surface IgM and it regulates transmembrane calcium conductance, cell cycle progression and B-cell proliferation
• CD20 is also associated with lipid rafts, but the intensity of this association depends on extracellular triggering, employing CD20 conformational change, and/or BCR (B cell antigen receptor) aggregation
• After the receptor ligation, BCR and CD20 colocalize and then rapidly dissociate before BCR endocytosis, whereas CD20 remains at the cell surface
• CD20 serves as a useful target for antibody-mediated therapeutic depletion of B cells, as it is expressed at high levels on most B-cell malignancies, but does not become internalized or shed from the plasma membrane following monoclonal antibody treatment
• Diseases associated with CD20 dysfunction include Ms4a1-related common variable immune deficiency.